Literature DB >> 14732472

Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects.

Laurence Baril1, Ludovic Nicolas, Bernard Croisile, Pierre Crozier, Catherine Hessler, Agnès Sassolas, Joseph B McCormick, Emanuelle Trannoy.   

Abstract

To investigate the immune response to amyloid beta-peptide (Abeta: Abeta40 and Abeta42) in peripheral human blood, sera were obtained from 36 patients with Alzheimer's disease (AD) and 34 age-matched controls. ELISA assays were used to measure antibody concentrations to Abeta-peptides. T cell response was assessed using a lymphoproliferation assay. Both AD and control subjects had low and variable concentrations of antibodies against Abeta (predominantly IgG1). The mean antibody to Abeta concentrations did not differ between groups. No specific T cell response to Abeta-peptides was detected. Natural levels of antibodies to Abeta in peripheral blood are present in all human subjects and are unlikely to be useful in the identification of patients who would respond to potential AD immune therapy. Specific cellular immune responses to Abeta in human blood were not detected.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14732472     DOI: 10.1016/j.neulet.2003.10.071

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  17 in total

Review 1.  T-cells in Alzheimer's disease.

Authors:  Terrence Town; Jun Tan; Richard A Flavell; Mike Mullan
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

2.  Aging enhances release of exosomal cytokine mRNAs by Aβ1-42-stimulated macrophages.

Authors:  Masato Mitsuhashi; Dennis D Taub; Dimitrios Kapogiannis; Erez Eitan; Linda Zukley; Mark P Mattson; Luigi Ferrucci; Janice B Schwartz; Edward J Goetzl
Journal:  FASEB J       Date:  2013-09-06       Impact factor: 5.191

3.  A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.

Authors:  Yona Levites; Brian O'Nuallain; Rama Devudu Puligedda; Tomas Ondrejcak; Sharad P Adekar; Cindy Chen; Pedro E Cruz; Awilda M Rosario; Sallie Macy; Alexandra J Mably; Dominic M Walsh; Ruben Vidal; Alan Solomon; Daniel Brown; Michael J Rowan; Todd E Golde; Scott K Dessain
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

4.  Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.

Authors:  Bao-Xi Qu; Yunhua Gong; Carol Moore; Min Fu; Dwight C German; Ling-Yu Chang; Roger Rosenberg; Ramon Diaz-Arrastia
Journal:  J Neuroimmunol       Date:  2014-06-27       Impact factor: 3.478

Review 5.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

6.  Anti-amyloidogenic activity of IgGs contained in normal plasma.

Authors:  Brian O'Nuallain; Angela D Williams; Helen P McWilliams-Koeppen; Luis Acero; Alfred Weber; Hartmut Ehrlich; Hans P Schwarz; Alan Solomon
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 7.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

8.  Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults.

Authors:  Madalina Maftei; Franka Thurm; Vera Maria Leirer; Christine A F von Arnim; Thomas Elbert; Michael Przybylski; Iris-Tatjana Kolassa; Marilena Manea
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

9.  ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects.

Authors:  Andrea C Klaver; Mary P Coffey; Lynnae M Smith; David A Bennett; John M Finke; Loan Dang; David A Loeffler
Journal:  J Neuroinflammation       Date:  2011-08-09       Impact factor: 8.322

10.  Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly.

Authors:  Agnieszka Jóźwik; Jerzy Landowski; Leszek Bidzan; Tamas Fülop; Ewa Bryl; Jacek M Witkowski
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.